Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Gandara, D. R., Graziano, S. L., Leighl, N. B., Adjei, A. A., Schiller, J. H., Eastern Cooperative Oncology Grp AMER SOC CLINICAL ONCOLOGY. 2011
View details for Web of Science ID 000208880302153